Literature DB >> 6774992

Thyrotropin-releasing hormone provokes abnormal follicle-stimulating hormone (FSH) and luteinizing hormone responses in men who have pituitary adenomas and FSH hypersecretion.

P J Snyder, R Muzyka, J Johnson, R D Utiger.   

Abstract

Serum FSH ad LH concentrations after the administration of TRH were measured in 10 men who had pituitary adenomas associated with FSH hypersecretion. Similar measurements were made in 12 men who had pituitary adenomas but no FSH hypersecretion, in 10 age-matched, normal men, and in 5 men who had primary hypergonadism. The mean serum LH concentration in the men who had pituitary adenomas and FSH hypersecretion increased 136% after TRH administration, significantly greataer (P < 0.005) than the 48% increase in the normal men or the 51% increase in the men who had pituitary adenomas without FSH hypersecretion. Serum LH did not increase at all in the men who had primary hypoganadism. The serum FSH concentration did not increase in any of the normal men, in the men who had pituitary adenomas without FSH hypersecretion, or in the men who had primary hypogonadism, but did increase in 5 of the 10 men who had FSH hypersecretion; the mean increase in these 5 men was 38%. The exaggerated LH responses and the nonspecific FSH responses to TRH of the men who had pituitary adenomas associated with FSH hypersecretion suggest that control of both FSH and LH secretion by these adenomas is abnormal and, therefore, that these adenomas are likely gonadotroph cell adenomas.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6774992     DOI: 10.1210/jcem-51-4-744

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Paradoxical release of LH under TRH dynamic test in patients suffering from "psychogenic" erective sexual impotency: lack of neuroradiological signs for hypophyseal lesions.

Authors:  J J Legros; D Ferreira de Almeida; J Servais; P Chiodera; A Thibaut; P Franchimont
Journal:  J Endocrinol Invest       Date:  1983-04       Impact factor: 4.256

2.  TRH is a tonic secretagogue in growth hormone secreting but not in nonfunctioning pituitary tumors.

Authors:  D Somjen; K Tordjman; Y Greenman; F Kohen; G E Ouaknine; N Stern
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

3.  Follicle stimulating hormone-secreting pituitary adenoma: inappropriate secretion and effect of pulsatile luteinizing hormone releasing hormone analogue (buserelin) administration.

Authors:  S Damjanović; D Micić; V Popović; M Petakov; A Kendereski; M Sumarac; D Manojlović; J Mićić
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

4.  Gonadotrophin and free alpha-subunit secretion in patients with acromegaly and clinically non-functioning pituitary tumors: anterior pituitary function and the effect of thyrotrophin-releasing hormone.

Authors:  S S Damjanović; V P Popović; M S Petakov; M M Nikolic-Durović; M Z Doknić; M S Gligorović
Journal:  J Endocrinol Invest       Date:  1996-11       Impact factor: 4.256

5.  Somatotroph to thyrotroph cell transdifferentiation during experimental hypothyroidism - a light and electron-microscopy study.

Authors:  S Radian; M Coculescu; J F Morris
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

6.  Gonadotroph adenomas of the human pituitary: sex-related fine-structural dichotomy. A histologic, immunocytochemical, and electron-microscopic study of 30 tumors.

Authors:  E Horvath; K Kovacs
Journal:  Am J Pathol       Date:  1984-12       Impact factor: 4.307

7.  Serum FSH bioactivity and inhibin levels in patients with gonadotropin secreting and nonfunctioning pituitary adenomas.

Authors:  S Borgato; L Persani; R Romoli; D Cortelazzi; A Spada; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

8.  Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas.

Authors:  P Chanson; N Lahlou; A Warnet; M Roger; G Sassolas; J Lubetzi; G Schaison; P Bouchard
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

9.  Usefulness of thyrotropin-releasing hormone test, SMS 201-995, and bromocriptine in the diagnosis and treatment of gonadotropin-secreting pituitary adenomas.

Authors:  C Blanco; T Lucas; J Alcañiz; N Davila; P Serrano; B Barcelò; J Estrada
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.